156 related articles for article (PubMed ID: 23133535)
1. Phospho-Akt immunoreactivity in prostate cancer: relationship to disease severity and outcome, Ki67 and phosphorylated EGFR expression.
Hammarsten P; Cipriano M; Josefsson A; Stattin P; Egevad L; Granfors T; Fowler CJ
PLoS One; 2012; 7(10):e47994. PubMed ID: 23133535
[TBL] [Abstract][Full Text] [Related]
2. Tumour Cannabinoid CB(1) receptor and phosphorylated epidermal growth factor receptor expression are additive prognostic markers for prostate cancer.
Fowler CJ; Hammarsten P; Bergh A
PLoS One; 2010 Dec; 5(12):e15205. PubMed ID: 21203460
[TBL] [Abstract][Full Text] [Related]
3. ErbB2 receptor immunoreactivity in prostate cancer: relationship to the androgen receptor, disease severity at diagnosis and disease outcome.
Hammarsten P; Winther J; Rudolfsson SH; Häggström J; Karalija A; Egevad L; Granfors T; Fowler CJ
PLoS One; 2014; 9(9):e105063. PubMed ID: 25215939
[TBL] [Abstract][Full Text] [Related]
4. Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4.
Thors L; Bergh A; Persson E; Hammarsten P; Stattin P; Egevad L; Granfors T; Fowler CJ
PLoS One; 2010 Aug; 5(8):e12275. PubMed ID: 20808855
[TBL] [Abstract][Full Text] [Related]
5. Association between cannabinoid CB₁ receptor expression and Akt signalling in prostate cancer.
Cipriano M; Häggström J; Hammarsten P; Fowler CJ
PLoS One; 2013; 8(6):e65798. PubMed ID: 23755281
[TBL] [Abstract][Full Text] [Related]
6. TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers.
Hägglöf C; Hammarsten P; Strömvall K; Egevad L; Josefsson A; Stattin P; Granfors T; Bergh A
PLoS One; 2014; 9(2):e86824. PubMed ID: 24505269
[TBL] [Abstract][Full Text] [Related]
7. Tumour epithelial expression levels of endocannabinoid markers modulate the value of endoglin-positive vascular density as a prognostic marker in prostate cancer.
Fowler CJ; Josefsson A; Thors L; Chung SC; Hammarsten P; Wikström P; Bergh A
Biochim Biophys Acta; 2013 Oct; 1831(10):1579-87. PubMed ID: 23262399
[TBL] [Abstract][Full Text] [Related]
8. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation.
Bedolla R; Prihoda TJ; Kreisberg JI; Malik SN; Krishnegowda NK; Troyer DA; Ghosh PM
Clin Cancer Res; 2007 Jul; 13(13):3860-7. PubMed ID: 17606718
[TBL] [Abstract][Full Text] [Related]
9. Low levels of phosphorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients.
Hammarsten P; Karalija A; Josefsson A; Rudolfsson SH; Wikström P; Egevad L; Granfors T; Stattin P; Bergh A
Clin Cancer Res; 2010 Feb; 16(4):1245-55. PubMed ID: 20145160
[TBL] [Abstract][Full Text] [Related]
10. A systems-based modelling approach using transurethral resection of the prostate (TURP) specimens yielded incremental prognostic significance to Gleason when predicting long-term outcome in men with localized prostate cancer.
Donovan MJ; Khan FM; Bayer-Zubek V; Powell D; Costa J; Cordon-Cardo C
BJU Int; 2012 Jan; 109(2):207-13. PubMed ID: 21733075
[TBL] [Abstract][Full Text] [Related]
11. Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas.
Magkou C; Nakopoulou L; Zoubouli C; Karali K; Theohari I; Bakarakos P; Giannopoulou I
Breast Cancer Res; 2008; 10(3):R49. PubMed ID: 18522728
[TBL] [Abstract][Full Text] [Related]
12. Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome.
Hammarsten P; Josefsson A; Thysell E; Lundholm M; Hägglöf C; Iglesias-Gato D; Flores-Morales A; Stattin P; Egevad L; Granfors T; Wikström P; Bergh A
Mod Pathol; 2019 Sep; 32(9):1310-1319. PubMed ID: 30980038
[TBL] [Abstract][Full Text] [Related]
13. A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer.
Chung SC; Hammarsten P; Josefsson A; Stattin P; Granfors T; Egevad L; Mancini G; Lutz B; Bergh A; Fowler CJ
Eur J Cancer; 2009 Jan; 45(1):174-82. PubMed ID: 19056257
[TBL] [Abstract][Full Text] [Related]
14. Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer.
Andre F; Nahta R; Conforti R; Boulet T; Aziz M; Yuan LX; Meslin F; Spielmann M; Tomasic G; Pusztai L; Hortobagyi GN; Michiels S; Delaloge S; Esteva FJ
Ann Oncol; 2008 Feb; 19(2):315-20. PubMed ID: 17804473
[TBL] [Abstract][Full Text] [Related]
15. Pathobiological implications of the expression of EGFR, pAkt, NF-κB and MIC-1 in prostate cancer stem cells and their progenies.
Mimeault M; Johansson SL; Batra SK
PLoS One; 2012; 7(2):e31919. PubMed ID: 22384099
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer.
Kreisberg JI; Malik SN; Prihoda TJ; Bedolla RG; Troyer DA; Kreisberg S; Ghosh PM
Cancer Res; 2004 Aug; 64(15):5232-6. PubMed ID: 15289328
[TBL] [Abstract][Full Text] [Related]
17. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer.
Aleskandarany MA; Rakha EA; Ahmed MA; Powe DG; Ellis IO; Green AR
Breast Cancer Res Treat; 2011 Jun; 127(2):407-16. PubMed ID: 20617378
[TBL] [Abstract][Full Text] [Related]
19. Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men.
Shimizu Y; Segawa T; Inoue T; Shiraishi T; Yoshida T; Toda Y; Yamada T; Kinukawa N; Terada N; Kobayashi T; Kinoshita H; Kamoto T; Nakamura E; Ogawa O
BJU Int; 2007 Sep; 100(3):685-90. PubMed ID: 17542985
[TBL] [Abstract][Full Text] [Related]
20. Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance.
Josefsson A; Wikström P; Egevad L; Granfors T; Karlberg L; Stattin P; Bergh A
Scand J Urol Nephrol; 2012 Aug; 46(4):247-57. PubMed ID: 22452635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
